- 32
- 9 683
Actinogen Medical
Australia
Приєднався 28 жов 2015
Actinogen Medical (ASX:ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. The company is currently developing its lead compound, Xanamem®, as a promising new therapy for Alzheimer’s disease, Fragile X and other neurological diseases
The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.
The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.
ACW $11. 1m Capital Raising
Today Actinogen Medical announced a $11m capital raising to accelerate its Alzheimer's Phase 2b/3 trial to full enrolment. An institutional placement of $7.0m was 2 x oversubscribed, with CEO Steven Gourlay investing a further $1m in the placement alongside commitments from other directors. Shareholders to participate via a $3m SPP on the same terms.
Переглядів: 419
Відео
ACW updated Depression Trial Results and implications
Переглядів 5242 місяці тому
See Actinogen CEO, Dr Steven Gourlay, CMO Dr Dana Hilt and commercial leader Mr Andy Udell present the positive and consistent XanaCIDD depression trial data announced on Monday 26 August, how the trial results teach about Xanamem’s cortisol control mechanism, and the outlook for Actinogen’s depression trial program.
XanaCIDD Topline Results Webinar Recording
Переглядів 3622 місяці тому
Please see today's webinar at which Actinogen CEO, Dr Steven Gourlay and CMO, Dr Dana Hilt present the top line results from the company's recent clinical trial in cognition and depression. US psychiatry trials expert, Dr Steven Targum MD also joins the presentation and Q&A to discuss the clinical trial results.
Wrap up - Australian Dementia Research Forum 2024 from Dr Jack Taylor
Переглядів 1015 місяців тому
Actinogen’s Dr Jack Taylor wraps up and gives his thoughts on the 2024 Australian Dementia Research Forum.
ACW Australian Dementia Research Forum poster presentation
Переглядів 2015 місяців тому
Actinogen’s Dr Jack Taylor discusses Xanamem academic poster being presented today at the Australian Dementia Research Forum
Actinogen Clinical Trials Science Forum 2024 - Pipeline in a Pill
Переглядів 4115 місяців тому
Actinogen Chief Medical Officer, Dr Dana Hilt and guests Professors John Harrison and Paul Rolan explore the unique properties of Xanamem for the potential treatment of cognitive impairment in multiple diseases. This is a plain English panel discussion. The presentation proper commences at 5.25
Actinogen May 2024 capital raising webinar
Переглядів 2636 місяців тому
CEO, Steven Gourlay and CFO, Will Souter outline the company's $8.9m capital raising announced 3 May 2024.
ACW CMO Dr Dana Hilt presents at Sachs Neuroscience Forum
Переглядів 1939 місяців тому
Dr Hilt's presentation recaps the success of Xanamem,® ACW’s novel pro-cognitive and potentially disease-modifying small molecule drug and examines the two near-term major Phase 2 readouts in Depression and Alzheimer's disease in 2024 and 2025 respectively.
Actinogen fireside chat 31 August 2023
Переглядів 860Рік тому
Professor Paul Maruff joins Actinogen’s Chief Medical Officer and neurologist Dr Dana Hilt MD to discuss recent progress in the Alzheimer’s disease (AD) field and cognitive impairment associated with depressive disorder (CIDD). This highly informative ‘plain English’ interview and discussion focuses on interpreting the various testing methods that have been applied to cognition in AD and CIDD a...
ACW Clinical Trials Science Forum 2023: Alzheimer’s: amyloid therapies are only part of the answer
Переглядів 288Рік тому
Actinogen Medical (ASX : ACW) held its Clinical Trials Science Forum via webcast on 24 May. ‘Following the Science’ is fundamental to all Actinogen’s activities. This plain english presentation is designed to explain the science behind targeting amyloid in Alzheimer’s disease and the opportunity for non-amyloid treatments such as Xanamem. Hear from ACW executive team members as they explore the...
Actinogen Medical: 2022 Annual General Meeting
Переглядів 193Рік тому
Our hybrid Annual General Meeting was held on 16 November 2022. Dr Geoff Brooke presented the Chair’s address and Dr. Steven Gourlay, CEO provided an update to shareholders. 00:00 Annual General Meeting 04:53 Chair's address 12:39 CEO's presentation 42:15 Formal business
Actinogen webcast positive Alzheimer’s Disease clinical results
Переглядів 6382 роки тому
Actinogen announced positive Phase 2a clinical data from its Alzheimer’s Disease biomarker study, which validates the Company’s Xanamem® program. Watch the recording of the webcast and Q&A session presented by CEO Dr Steven Gourlay and CMO Professor Paul Rolan for a more in-depth look at this very exciting news for the company.
Actinogen Clinical Trials Science Forum
Переглядів 4502 роки тому
Actinogen Medical (ASX : ACW) held its Clinical Trials Science Forum via webcast on 3 August. In case you missed it, a recording of the event is now available. It's well worth watching - you don't need a science background to understand the presentations. Our aim is to provide a deeper understanding of our company while limiting the science-speak and jargon. We are delighted to head our program...
Dr Steven Gourlay | Ticker Insight | Biotech Breakthrough: A clinical step for new Alzheimer’s trial
Переглядів 2502 роки тому
Watch this recent interview on Ticker Insight with Dr Steven Gourlay providing an update on Actinogen and our successful trial. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, and Xanamem has shown the ability to improve working memory and attention in healthy, older volunteers.
XanaMIA Part A Trial positive topline results for Xanamem - ACW Webcast 27 April 2022
Переглядів 2112 роки тому
Actinogen announced positive topline results for its XanaMIA Part A trial involving its small molecule drug Xanamem on 27 April 2022l. Watch the recording here of the webcast and Q&A session hosted by CEO Dr Steven Gourlay and CMO Professor Paul Rolan to get a more in-depth picture about this exciting news for the company.
Actinogen Medical Webcast 25 Nov 2021: Strategic Update & Capital Raising Investor presentation
Переглядів 1902 роки тому
Actinogen Medical Webcast 25 Nov 2021: Strategic Update & Capital Raising Investor presentation
Actinogen Medical: 2021 Annual General Meeting
Переглядів 2232 роки тому
Actinogen Medical: 2021 Annual General Meeting
Dr Steven Gourlay | Ticker News | Cognitive impairment: A drug for the treatment of Alzheimer's
Переглядів 1413 роки тому
Dr Steven Gourlay | Ticker News | Cognitive impairment: A drug for the treatment of Alzheimer's
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Переглядів 3244 роки тому
Actinogen Medical Conference Call 19 Oct 2020: Webcast presentation
Actinogen Medical: Dr Bill Ketelbey company presentation at BIO Digital 2020 (8-12 Jun)
Переглядів 3454 роки тому
Actinogen Medical: Dr Bill Ketelbey company presentation at BIO Digital 2020 (8-12 Jun)
Actinogen Medical: Managing Director's Address to Shareholders at AGM 25 Nov 2019
Переглядів 814 роки тому
Actinogen Medical: Managing Director's Address to Shareholders at AGM 25 Nov 2019
Actinogen Medical: Developing Xanamem as a promising new therapy for Alzheimer’s disease
Переглядів 4825 років тому
Actinogen Medical: Developing Xanamem as a promising new therapy for Alzheimer’s disease
Actinogen Medical: Taking a new approach to the treatment of Alzheimer’s disease
Переглядів 3435 років тому
Actinogen Medical: Taking a new approach to the treatment of Alzheimer’s disease
Actinogen Medical: Focussed on the treatment of Alzheimer’s disease
Переглядів 4355 років тому
Actinogen Medical: Focussed on the treatment of Alzheimer’s disease
Actinogen Medical: XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Переглядів 1605 років тому
Actinogen Medical: XanADu, Xanamem & Cortisol: Oct 2018 Barcelona
Actinogen Medical: Completion of Interim Analysis, capital raise of $15m and launch of SPP
Переглядів 326 років тому
Actinogen Medical: Completion of Interim Analysis, capital raise of $15m and launch of SPP
ASX:ACW Investor Open Briefing March 2018
Переглядів 5606 років тому
ASX:ACW Investor Open Briefing March 2018
ACW & KaRa Minds: Leading Alzheimer’s Researchers Address to Shareholders on 29 Nov 2017
Переглядів 3756 років тому
ACW & KaRa Minds: Leading Alzheimer’s Researchers Address to Shareholders on 29 Nov 2017
Meet the CEO & Chairman of Actinogen Medical
Переглядів 1628 років тому
Meet the CEO & Chairman of Actinogen Medical
The first share I ever bought :3 Now wait some years :D
Here's hoping.
Why is the piano making a noise, its difficult to listen